{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:02:40Z","timestamp":1772751760599,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,9,27]],"date-time":"2008-09-27T00:00:00Z","timestamp":1222473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2008,9,27]],"date-time":"2008-09-27T00:00:00Z","timestamp":1222473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1007\/s00262-008-0587-1","type":"journal-article","created":{"date-parts":[[2008,9,26]],"date-time":"2008-09-26T06:14:15Z","timestamp":1222409655000},"page":"653-664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["HER-2\/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice"],"prefix":"10.1007","volume":"58","author":[{"given":"Simona","family":"Vertuani","sequence":"first","affiliation":[]},{"given":"Chiara","family":"Triulzi","sequence":"additional","affiliation":[]},{"given":"Anna Karin","family":"Roos","sequence":"additional","affiliation":[]},{"given":"Jehad","family":"Charo","sequence":"additional","affiliation":[]},{"given":"H\u00e5kan","family":"Norell","sequence":"additional","affiliation":[]},{"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"additional","affiliation":[]},{"given":"Pavel","family":"Pisa","sequence":"additional","affiliation":[]},{"given":"Barbara","family":"Seliger","sequence":"additional","affiliation":[]},{"given":"Rolf","family":"Kiessling","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2008,9,27]]},"reference":[{"key":"587_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00262-005-0692-3","volume":"1","author":"CN Baxevanis","year":"2006","unstructured":"Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M (2006) Immunogenic HER-2\/neu peptides as tumor vaccines. Cancer Immunol Immunother 1:85\u201395","journal-title":"Cancer Immunol Immunother"},{"key":"587_CR2","first-page":"732","volume":"4","author":"P Brossart","year":"1998","unstructured":"Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W (1998) Her-2\/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 4:732\u2013736","journal-title":"Cancer Res"},{"key":"587_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/ijc.11497","volume":"1","author":"A Choudhury","year":"2004","unstructured":"Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, Kiessling R (2004) Small interfering RNA (siRNA) inhibits the expression of the Her2\/neu gene, upregulates HLA class I and induces apoptosis of Her2\/neu positive tumor cell lines. Int J Cancer 1:71\u201377","journal-title":"Int J Cancer"},{"key":"587_CR4","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/ijc.21098","volume":"6","author":"C Cuadros","year":"2005","unstructured":"Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgstrom P, Lustgarten J (2005) Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4\u20131BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2\/neu transgenic mice. Int J Cancer 6:934\u2013943","journal-title":"Int J Cancer"},{"key":"587_CR5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/0092-8674(91)90037-Y","volume":"6","author":"M Del Val","year":"1991","unstructured":"Del Val M, Schlicht HJ, Ruppert T, Reddehase MJ, Koszinowski UH (1991) Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 6:1145\u20131153","journal-title":"Cell"},{"key":"587_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1023\/B:JOCI.0000040928.67495.52","volume":"5","author":"ML Disis","year":"2004","unstructured":"Disis ML, Goodell V, Schiffman K, Knutson KL (2004) Humoral epitope-spreading following immunization with a HER-2\/neu peptide based vaccine in cancer patients. J Clin Immunol 5:571\u2013578","journal-title":"J Clin Immunol"},{"key":"587_CR7","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1084\/jem.181.6.2109","volume":"6","author":"B Fisk","year":"1995","unstructured":"Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2\/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 6:2109\u20132117","journal-title":"J Exp Med"},{"key":"587_CR8","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1158\/0008-5472.CAN-05-4018","volume":"10","author":"AD Gritzapis","year":"2006","unstructured":"Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN (2006) Vaccination with Human HER-2\/neu (435\u2013443) CTL peptide induces effective antitumor immunity against HER-2\/neu-expressing tumor cells in vivo. Cancer Res 10:5452\u20135460","journal-title":"Cancer Res"},{"key":"587_CR9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/153537020222700403","volume":"4","author":"K Haupt","year":"2002","unstructured":"Haupt K, Roggendorf M, Mann K (2002) The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp Biol Med (Maywood) 4:227\u2013237","journal-title":"Exp Biol Med (Maywood)"},{"key":"587_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/0008-5472.CAN-2522-2","volume":"1","author":"F Herrmann","year":"2004","unstructured":"Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, Seliger B (2004) HER-2\/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 1:215\u2013220","journal-title":"Cancer Res"},{"key":"587_CR11","first-page":"2950","volume":"12","author":"S Horiguchi","year":"1999","unstructured":"Horiguchi S, Petersson M, Nakazawa T, Kanda M, Zea AH, Ochoa AC, Kiessling R (1999) Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res 12:2950\u20132956","journal-title":"Cancer Res"},{"key":"587_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00262-005-0050-5","volume":"6","author":"BL Kaplan","year":"2006","unstructured":"Kaplan BL, Norell H, Callender GG, Ohlum T, Kiessling R, Nishimura MI (2006) Interferon-gamma renders tumors that express low levels of Her-2\/neu sensitive to cytotoxic T cells. Cancer Immunol Immunother 6:653\u2013662","journal-title":"Cancer Immunol Immunother"},{"key":"587_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0198-8859(97)00255-3","volume":"1","author":"I Kawashima","year":"1998","unstructured":"Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E (1998) The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1:1\u201314","journal-title":"Hum Immunol"},{"key":"587_CR14","doi-asserted-by":"crossref","unstructured":"Kiessling R, Wei WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K, Seliger B (2002) Cellular immunity to the Her-2\/neu protooncogene. Adv Cancer Res 101\u2013144","DOI":"10.1016\/S0065-230X(02)85004-7"},{"key":"587_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1172\/JCI11752","volume":"4","author":"KL Knutson","year":"2001","unstructured":"Knutson KL, Schiffman K, Disis ML (2001) Immunization with a HER-2\/neu helper peptide vaccine generates HER-2\/neu CD8 T-cell immunity in cancer patients. J Clin Invest 4:477\u2013484","journal-title":"J Clin Invest"},{"key":"587_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/(SICI)1097-0215(19970106)70:1<112::AID-IJC17>3.0.CO;2-N","volume":"1","author":"K Kono","year":"1997","unstructured":"Kono K, Halapi E, Hising C, Petersson M, Gerdin E, Vanky F, Kiessling R (1997) Mechanisms of escape from CD8+\u00a0T-cell clones specific for the HER-2\/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression. Int J Cancer 1:112\u2013119","journal-title":"Int J Cancer"},{"key":"587_CR17","doi-asserted-by":"crossref","unstructured":"Leifert JA, Rodriguez-Carreno MP, Rodriguez F, Whitton JL (2004) Targeting plasmid-encoded proteins to the antigen presentation pathways. Immunol Rev 40\u201353","DOI":"10.1111\/j.0105-2896.2004.0135.x"},{"key":"587_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ijc.11654","volume":"2","author":"JA Lindencrona","year":"2004","unstructured":"Lindencrona JA, Preiss S, Kammertoens T, Schuler T, Piechocki M, Wei WZ, Seliger B, Blankenstein T, Kiessling R (2004) CD4+\u00a0T cell-mediated HER-2\/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2:259\u2013264","journal-title":"Int J Cancer"},{"key":"587_CR19","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/(SICI)1097-0215(19980911)77:6<937::AID-IJC24>3.0.CO;2-X","volume":"6","author":"PL Lollini","year":"1998","unstructured":"Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Rossi I, Di Carlo E, Musiani P, Muller WJ, Nanni P (1998) Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2\/neu transgenic mice. Int J Cancer 6:937\u2013941","journal-title":"Int J Cancer"},{"key":"587_CR20","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/eji.200324427","volume":"3","author":"J Lustgarten","year":"2004","unstructured":"Lustgarten J, Dominguez AL, Cuadros C (2004) The CD8+\u00a0T cell repertoire against Her-2\/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur J Immunol 3:752\u2013761","journal-title":"Eur J Immunol"},{"key":"587_CR21","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1084\/jem.185.12.2043","volume":"12","author":"S Pascolo","year":"1997","unstructured":"Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B (1997) HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2\u00a0m) HLA-A2.1 monochain transgenic H-2Db beta2\u00a0m double knockout mice. J Exp Med 12:2043\u20132051","journal-title":"J Exp Med"},{"key":"587_CR22","doi-asserted-by":"publisher","first-page":"7536","DOI":"10.1200\/JCO.2005.03.047","volume":"30","author":"GE Peoples","year":"2005","unstructured":"Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S (2005) Clinical trial results of a HER2\/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 30:7536\u20137545","journal-title":"J Clin Oncol"},{"key":"587_CR23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1158\/1078-0432.CCR-07-1448","volume":"3","author":"GE Peoples","year":"2008","unstructured":"Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S (2008) Combined clinical trial results of a HER2\/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 3:797\u2013803","journal-title":"Clin Cancer Res"},{"key":"587_CR24","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.4049\/jimmunol.171.11.5787","volume":"11","author":"MP Piechocki","year":"2003","unstructured":"Piechocki MP, Ho YS, Pilon S, Wei WZ (2003) Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 11:5787\u20135794","journal-title":"J Immunol"},{"key":"587_CR25","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1158\/0008-5472.CAN-03-2962","volume":"8","author":"E Quaglino","year":"2004","unstructured":"Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F (2004) Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2\/neu transgenic mice. Cancer Res 8:2858\u20132864","journal-title":"Cancer Res"},{"key":"587_CR26","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1128\/JVI.72.6.5174-5181.1998","volume":"6","author":"F Rodriguez","year":"1998","unstructured":"Rodriguez F, An LL, Harkins S, Zhang J, Yokoyama M, Widera G, Fuller JT, Kincaid C, Campbell IL, Whitton JL (1998) DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol 6:5174\u20135181","journal-title":"J Virol"},{"key":"587_CR27","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4049\/jimmunol.163.2.1037","volume":"2","author":"Y Rongcun","year":"1999","unstructured":"Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R (1999) Identification of new HER2\/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 2:1037\u20131044","journal-title":"J Immunol"},{"key":"587_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ymthe.2005.08.005","volume":"2","author":"AK Roos","year":"2006","unstructured":"Roos AK, Moreno S, Leder C, Pavlenko M, King A, Pisa P (2006) Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 2:320\u2013327","journal-title":"Mol Ther"},{"key":"587_CR29","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.1158\/0008-5472.CAN-06-3998","volume":"14","author":"A Scardino","year":"2007","unstructured":"Scardino A, Alimandi M, Correale P, Smith SG, Bei R, Firat H, Cusi MG, Faure O, Graf-Dubois S, Cencioni G, Marrocco J, Chouaib S, Lemonnier FA, Jackson AM, Kosmatopoulos K (2007) A polyepitope DNA vaccine targeted to Her-2\/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge. Cancer Res 14:7028\u20137036","journal-title":"Cancer Res"},{"key":"587_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/1097-0215(20000801)87:3<349::AID-IJC7>3.0.CO;2-O","volume":"3","author":"B Seliger","year":"2000","unstructured":"Seliger B, Rongcun Y, Atkins D, Hammers S, Huber C, Storkel S, Kiessling R (2000) HER-2\/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer 3:349\u2013359","journal-title":"Int J Cancer"},{"key":"587_CR31","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1073\/pnas.83.15.5620","volume":"15","author":"S Torsteinsdottir","year":"1986","unstructured":"Torsteinsdottir S, Masucci MG, Ehlin-Henriksson B, Brautbar C, Ben Bassat H, Klein G, Klein E (1986) Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc Natl Acad Sci USA 15:5620\u20135624","journal-title":"Proc Natl Acad Sci USA"},{"key":"587_CR32","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s002510100353","volume":"6","author":"TM Tran","year":"2001","unstructured":"Tran TM, Ivanyi P, Hilgert I, Brdicka T, Pla M, Breur B, Flieger M, Ivaskova E, Horejsi V (2001) The epitope recognized by pan-HLA class I-reactive monoclonal antibody W6\/32 and its relationship to unusual stability of the HLA-B27\/beta2-microglobulin complex. Immunogenetics 6:440\u2013446","journal-title":"Immunogenetics"},{"key":"587_CR33","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<748::AID-IJC14>3.0.CO;2-6","volume":"5","author":"WZ Wei","year":"1999","unstructured":"Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B, Heilbrun L, Jones RF (1999) Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 5:748\u2013754","journal-title":"Int J Cancer"},{"key":"587_CR34","first-page":"4902","volume":"21","author":"TZ Zaks","year":"1998","unstructured":"Zaks TZ, Rosenberg SA (1998) Immunization with a peptide epitope (p369\u2013377) from HER-2\/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2\/neu+ tumors. Cancer Res 21:4902\u20134908","journal-title":"Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-008-0587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-008-0587-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-008-0587-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-008-0587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:17:26Z","timestamp":1744165046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-008-0587-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,27]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["587"],"URL":"https:\/\/doi.org\/10.1007\/s00262-008-0587-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,27]]},"assertion":[{"value":"20 May 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}